Navigation Links
HIV infection requires an accomplice: B cells with special protein direct HIV to T cells

HIV infection of T cells requires activation of a molecule on the surface of B cells, a finding that reveals yet another pathway the virus uses in its insidious attack on the immune system, University of Pittsburgh researchers will report at the XVI International AIDS Conference (AIDS 2006).

"The research supports a new role for B cells in the development and spread of HIV between cells, with important implications for future studies and drug development efforts that focus on reservoirs of HIV in cells other than T cells," said Charles R. Rinaldo, Jr., Ph.D., professor and chairman of the department of infectious diseases and microbiology at Pitt's Graduate School of Public Health (GSPH) and the study's senior author.

Nearly all approved HIV drug regimens and most of those being tested in clinical trials focus on T cells of the immune system, where HIV replicates and thrives. HIV hijacks T cells by binding to a cell membrane molecule called CD4 and to either or both of two other receptors, from which the two strains of HIV, X4 and C5, take their names. Once anchored on the membrane, it's able to slither inside and take command of the cell. But as the Pitt studies have found, there is an important first step in a new pathway involving B cells that express a protein called DC-SIGN. B cells are key players in an immune response.

While these cells themselves do not become infected, they play a pivotal role as an accomplice in HIV's takeover of T cells.

According to the research to be reported by Giovanna Rappocciolo, Ph.D., research assistant professor of infectious diseases and microbiology at GSPH, laboratory studies provide evidence of DC-SIGN in subsets of B cells from both healthy subjects and HIV infected individuals and indicate DC-SIGN is both a point of entry for HIV and necessary for T cell infection.

B cells were isolated from blood samples obtained in 33 healthy subjects and 20 adult patients with HIV from the Mul ticenter AIDS Cohort Study (MACS). Researchers found about 8 percent of these cells expressed DC-SIGN.

In one set of studies involving cells from the healthy subjects, the team activated DC-SIGN using two molecules that T cells typically engage in their communication with B cells. Once activated, the DC-SIGN B cells were placed in a culture with T cells and a small amount of virus. Within 24 hours, HIV had begun invading the T cells, yet the B cells were spared. Although they did not become infected, B cells nonetheless harbored virus that was transmissible to T cells for up to two days. HIV had little effect on the T cells when B cells were not present in the culture. Pretreating the B cells with a molecule that blocks DC-SIGN before culturing them with both T cells and HIV was a deterrent against T cell infection as well, further proof that to invade T cells, HIV requires DC-SIGN to be expressed on B cells.


'"/>

Source:University of Pittsburgh Medical Center


Related biology news :

1. Dysentery uses sword and shield to cause infection
2. Topical treatment shown to inhibit HIV and herpes simplex virus infection
3. Novel antiviral technology inhibits RSV infection in mice
4. Bacteria collection sheds light on urinary tract infections
5. Scientists decipher genome of fungus that can cause life-threatening infections
6. Yale researchers identify molecule for detecting parasitic infection in humans
7. Molecule that usually protects infection-fighting cells may cause plaque deposits inside arteries
8. Light therapy may combat fungal infections, new evidence suggests
9. Gladstone investigators discover how resting T cells avoid HIV infection
10. New strategies to reduce hospital-aquired infections
11. Virologists make major step towards understanding the process of HIV infection
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/3/2016)... -- FlexTech, a SEMI Strategic Association Partner, awarded five FLEXI ... Leadership in Education, and, in a category new this ... year of the FLEXI Awards and the winners join ... past years . Judging was done on a set ... by a panel of non-affiliated, independent, industry experts. ...
(Date:3/3/2016)... DE SOTO, Kansas , March 3, 2016 ... to offer Oncimmune,s Early CDT®-Lung, a blood test ... of lung cancer Early CDT®-Lung test to ... --> Early CDT®-Lung test to its clients ... Oncimmune, a leader in early cancer detection, today ...
(Date:3/2/2016)... , March 2, 2016 ... addition of the "Global Biometrics as ... their offering. --> http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ... "Global Biometrics as a Service Market ... --> Research and Markets ( ...
Breaking Biology News(10 mins):
(Date:4/26/2016)... ... , ... The European Patent Office (EPO) today announced that ... the European Inventor Award 2016 in the category "Non-European countries." The winners of the ... in Lisbon on June 9th. , The human capacity to walk with fluidity is ...
(Date:4/26/2016)... CA (PRWEB) , ... April 26, 2016 , ... Mr. ... for Adecco RPO, signing the first multi-million dollar, multi-year managed services contract in the ... to have Michael join our leadership team,” said John Younger, founder of Accolo. ...
(Date:4/26/2016)... ... April 26, 2016 , ... BioFactura, Inc ., a biopharmaceutical research ... financing. Healthy investor interest drove significant oversubscription of the original $1.5M target. ... biosimilars, to the advanced preclinical stages. , Chief Executive Officer and President, Darryl ...
(Date:4/26/2016)... BUDAPEST, Hungary , VIENNA ... 26, 2016 The prize ... and the resulting revolutionary innovations that will benefit ... (Logo: http://photos.prnewswire.com/prnh/20160210/331945LOGO ) , ... developing novel proprietary trend setting products in the ...
Breaking Biology Technology: